Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) PT at $62.25

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has earned an average recommendation of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $62.25.

Several equities analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Thursday, December 19th. The Goldman Sachs Group initiated coverage on shares of Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective on the stock. Wolfe Research cut Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Monday, September 16th. Finally, Citigroup assumed coverage on Celldex Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $70.00 price target for the company.

Celldex Therapeutics Stock Performance

Shares of NASDAQ CLDX opened at $25.27 on Friday. The stock has a market capitalization of $1.68 billion, a P/E ratio of -9.83 and a beta of 1.57. The stock’s fifty day moving average is $26.17 and its 200 day moving average is $32.81. Celldex Therapeutics has a 52 week low of $22.93 and a 52 week high of $53.18.

Insider Transactions at Celldex Therapeutics

In other news, CEO Anthony S. Marucci purchased 11,500 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the acquisition, the chief executive officer now owns 40,284 shares in the company, valued at $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Celldex Therapeutics

Several institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP boosted its position in shares of Celldex Therapeutics by 14.5% in the third quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock valued at $314,190,000 after acquiring an additional 1,167,659 shares during the period. Bellevue Group AG raised its holdings in shares of Celldex Therapeutics by 3.4% during the 3rd quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock valued at $104,404,000 after buying an additional 100,000 shares in the last quarter. Point72 Asset Management L.P. raised its stake in shares of Celldex Therapeutics by 51.0% during the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock worth $71,725,000 after acquiring an additional 654,194 shares in the last quarter. Geode Capital Management LLC lifted its stake in Celldex Therapeutics by 0.4% in the third quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company’s stock worth $52,372,000 after purchasing an additional 6,557 shares during the last quarter. Finally, Marshall Wace LLP boosted its holdings in Celldex Therapeutics by 53.3% during the 2nd quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock valued at $50,995,000 after acquiring an additional 479,068 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.